Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced significant updates in its research and development programs. The company is on track to submit a New Drug Application (NDA) for bitopertin in the treatment of erythropoietic protoporphyria $(EPP.UK)$ under the accelerated approval pathway by October 2025. This submission follows a successful pre-NDA meeting. Additionally, Disc Medicine anticipates initial data from its Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) and multiple dose data from a Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) in the fourth quarter of 2025. The company has also initiated a Phase 2 study of DISC-3405 in polycythemia vera, with initial data expected in 2026. The clinical data from the continuation phase of the Phase 1b trial of DISC-0974 in MF anemia was presented at EHA 2025, demonstrating a durable hematologic response. These developments indicate continued progress across Disc Medicine's pipeline.